BioAffinity Technologies Revenue vs. Total Debt

BIAFW Stock  USD 0.57  0.13  18.57%   
Based on BioAffinity Technologies' profitability indicators, bioAffinity Technologies Warrant may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess BioAffinity Technologies' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
2.5 M
Current Value
2.7 M
Quarterly Volatility
913.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
EV To Sales is likely to climb to 4.82 in 2024, whereas Price To Sales Ratio is likely to drop 4.82 in 2024. At this time, BioAffinity Technologies' Total Other Income Expense Net is fairly stable compared to the past year. Income Tax Expense is likely to climb to about 22 K in 2024, despite the fact that Operating Income is likely to grow to (7.6 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.30.3126
Sufficiently Down
Slightly volatile
For BioAffinity Technologies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioAffinity Technologies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well bioAffinity Technologies Warrant utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioAffinity Technologies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of bioAffinity Technologies Warrant over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.744
Quarterly Revenue Growth
120.474
Return On Assets
(0.70)
Return On Equity
(1.52)
The market value of BioAffinity Technologies is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies' value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies' market value can be influenced by many factors that don't directly affect BioAffinity Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioAffinity Technologies Total Debt vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies's current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies value to that of its competitors to determine the firm's financial worth.
bioAffinity Technologies Warrant is the top company in revenue category among its peers. It also is the top company in total debt category among its peers making up about  0.62  of Total Debt per Revenue. The ratio of Revenue to Total Debt for bioAffinity Technologies Warrant is roughly  1.60 . At this time, BioAffinity Technologies' Total Revenue is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

BioAffinity Revenue vs. Competition

bioAffinity Technologies Warrant is the top company in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 41.61 Million. BioAffinity Technologies holds roughly 2.53 Million in revenue claiming about 6% of equities under Health Care industry.

BioAffinity Total Debt vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

BioAffinity Technologies

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
2.53 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

BioAffinity Technologies

Total Debt

 = 

Bonds

+

Notes

 = 
1.58 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

BioAffinity Total Debt vs Competition

bioAffinity Technologies Warrant is the top company in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 9.47 Million. BioAffinity Technologies retains roughly 1.58 Million in total debt claiming about 17% of equities under Health Care industry.
Total debt  Revenue  Valuation  Workforce  Capitalization

BioAffinity Technologies Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioAffinity Technologies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioAffinity Technologies will eventually generate negative long term returns. The profitability progress is the general direction of BioAffinity Technologies' change in net profit over the period of time. It can combine multiple indicators of BioAffinity Technologies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.6 M-3.8 M
Operating Income-8 M-7.6 M
Income Before Tax-7.9 M-8.3 M
Total Other Income Expense Net57.2 K60.1 K
Net Loss-7.9 M-8.3 M
Income Tax Expense21 K22 K
Net Interest Income47.3 K49.7 K
Interest Income148.4 K155.8 K
Net Loss-7.2 M-7.6 M
Net Loss(0.91)(0.95)
Income Quality 0.76  0.42 
Net Income Per E B T 1.00  0.80 

BioAffinity Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioAffinity Technologies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioAffinity Technologies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioAffinity Technologies' important profitability drivers and their relationship over time.

Use BioAffinity Technologies in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioAffinity Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioAffinity Technologies will appreciate offsetting losses from the drop in the long position's value.

BioAffinity Technologies Pair Trading

bioAffinity Technologies Warrant Pair Trading Analysis

The ability to find closely correlated positions to BioAffinity Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioAffinity Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioAffinity Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling bioAffinity Technologies Warrant to buy it.
The correlation of BioAffinity Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioAffinity Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioAffinity Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioAffinity Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your BioAffinity Technologies position

In addition to having BioAffinity Technologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Petroleum and Natural Gas Thematic Idea Now

Petroleum and Natural Gas
Petroleum and Natural Gas Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Petroleum and Natural Gas theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Petroleum and Natural Gas Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for BioAffinity Stock Analysis

When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.